<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="a63eae1f-df0d-4671-a18c-f9e609634446"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use DUEXIS<sup>Â®</sup> safely and effectively. See full prescribing information for DUEXIS.<br/>
      <br/>DUEXIS (ibuprofen and famotidine) tablets, for oral use<br/>Initial U.S. Approval: 2011</title>
   <effectiveTime value="20200327"/>
   <setId root="558b9f26-37b2-423b-932d-25a37afe57ec"/>
   <versionNumber value="12"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="033470838" root="1.3.6.1.4.1.519.1"/>
            <name>Horizon Therapeutics USA, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="dce5803b-05be-4c98-b3e9-60bd7776615c"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20190731"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="75987-010" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>DUEXIS</name>
                        <formCode code="C42897" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Ibuprofen and Famotidine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="800" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="WK2XYI10QM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ibuprofen</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="WK2XYI10QM" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Ibuprofen</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="26.6" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="5QZO15J2Z8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Famotidine</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="5QZO15J2Z8" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Famotidine</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="J2B2A4N98G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE, UNSPECIFIED FORM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4AQJ3LG584" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 2--ALUMINUM LAKE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE No. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="75987-010-03" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20111205"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="3" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="9" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="75987-010-72" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20111205"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA022519" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20111205"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLUE" xsi:type="CE">
                              <originalText>Light Blue</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="19" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">HZT</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="BOX">
               <id root="855a1ae9-758b-468b-8019-bdcfd8918fa6"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>
                  <content styleCode="emphasis">WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS</content>
               </title>
               <effectiveTime value="20190731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS</paragraph>
                        <paragraph>
                           <content styleCode="italics">See full prescribing information for complete boxed warning</content>.</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="bold">Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (<linkHtml href="#S5.1">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">DUEXIS is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (<linkHtml href="#S4">4</linkHtml>, <linkHtml href="#S5.1">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events (<linkHtml href="#S5.2">5.2</linkHtml>)</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="e4ca7304-d664-418b-a890-94fc88760208"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold underline">Cardiovascular Thrombotic Events</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="bold">Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</content>
                           </item>
                           <item>
                              <content styleCode="bold">DUEXIS is contraindicated in the setting of coronary artery bypass graft (CABG) surgery <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml> and <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].</content>
                              </content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="fd74de6f-0174-4cfd-a63a-cfa920bccd16"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold underline">Gastrointestinal Bleeding, Ulceration, and Perforation</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="bold">NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and   perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="985de89a-613b-4604-bf9a-c946407d234c"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>DUEXIS, a combination of the NSAID ibuprofen and the histamine H<sub>2</sub>-receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are  taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>, <linkHtml href="#S8.5">Use in Specific Populations (8.5)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20190731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>DUEXIS, a combination of a nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the histamine H<sub>2</sub>-receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="94648aab-124c-4e55-9184-74478474ca26"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Carefully consider the potential benefits and risks of DUEXIS and other treatment options before deciding to use DUEXIS.  Use ibuprofen at the lowest effective dosage for the shortest duration consistent with individual patient treatment goals <content styleCode="italics">[see <linkHtml href="#S5">Warnings and Precautions (5)</linkHtml>]</content>.</paragraph>
                  <paragraph>The recommended daily dose of DUEXIS (ibuprofen and famotidine) 800 mg/26.6 mg is a single tablet administered orally three times per day.</paragraph>
                  <paragraph>DUEXIS tablets should be swallowed whole, and should not be cut to supply a lower dose. Do not chew, divide, or crush tablets.</paragraph>
                  <paragraph>Patients should be instructed that if a dose is missed, it should be taken as soon possible. However, if the next scheduled dose is due, the patient should not take the missed dose, and should be instructed to take the next dose on time. Patients should be instructed not to take 2 doses at one time to make up for a missed dose.</paragraph>
                  <paragraph>Do not substitute DUEXIS with the single-ingredient products of ibuprofen and famotidine.</paragraph>
               </text>
               <effectiveTime value="20190731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>One DUEXIS tablet administered orally three times per day. (<linkHtml href="#S2">2</linkHtml>)</item>
                           <item>Use ibuprofen at the lowest effective dosage for the shortest duration consistent with individual patient treatment goals. (<linkHtml href="#S2">2</linkHtml>)</item>
                           <item>Do not substitute DUEXIS with the single-ingredient products of ibuprofen and famotidine. (<linkHtml href="#S2">2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="3a5d175c-a9e6-4495-a8f8-5dc6af6bec62"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>DUEXIS (ibuprofen and famotidine) tablets: 800 mg/26.6 mg, are light blue, oval, biconvex, film-coated tablets debossed with "HZT" on one side.</paragraph>
               </text>
               <effectiveTime value="20190731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>DUEXIS (ibuprofen and famotidine) Tablets: 800 mg ibuprofen and 26.6 mg famotidine. (<linkHtml href="#S3">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="4591beec-408b-4d58-b574-8db739166afa"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>DUEXIS is contraindicated in the following patients:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to ibuprofen or famotidine or any components of the drug product <content styleCode="italics">[see <linkHtml href="#S5.8">Warnings and Precautions (5.8</linkHtml>, <linkHtml href="#S5.11">5.11)</linkHtml>]</content>.</item>
                     <item>History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients <content styleCode="italics">[see <linkHtml href="#S5.8">Warnings and Precautions (5.8</linkHtml>, <linkHtml href="#S5.10">5.10)</linkHtml>]</content>.</item>
                     <item>In the setting of coronary artery bypass graft (CABG) surgery <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</item>
                     <item>DUEXIS should not be administered to patients with a history of hypersensitivity to other H<sub>2</sub>-receptor antagonists. Cross sensitivity with other H<sub>2</sub>-receptor antagonists has been observed.</item>
                  </list>
               </text>
               <effectiveTime value="20190731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Known hypersensitivity to ibuprofen or famotidine or any components of the drug product. (<linkHtml href="#S4">4</linkHtml>)</item>
                           <item>History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. (<linkHtml href="#S4">4</linkHtml>)</item>
                           <item>In the setting of CABG surgery. (<linkHtml href="#S4">4</linkHtml>)</item>
                           <item>Known hypersensitivity to other H<sub>2</sub>-receptor antagonists. (<linkHtml href="#S4">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="6a989c99-e824-49a3-999f-f2c49d6f5c27"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20190731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="underline">Hepatotoxicity</content>:  Inform patients of warning signs and symptoms of hepatotoxicity. Discontinue if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop. (<linkHtml href="#S5.4">5.4</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Hypertension</content>:  Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Monitor blood pressure. (<linkHtml href="#S5.5">5.5</linkHtml>, <linkHtml href="#S7">7</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Heart Failure and Edema</content>: Avoid use of DUEXIS in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure. (<linkHtml href="#S5.6">5.6</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Active Bleeding</content>: Active and clinically significant bleeding from any source can occur; discontinue DUEXIS if active bleeding occurs. (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Renal Toxicity</content>: Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. Avoid use of DUEXIS in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function. (<linkHtml href="#S5.7">5.7</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Anaphylactic Reactions</content>: Seek emergency help if an anaphylactic reaction occurs. (<linkHtml href="#S5.8">5.8</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Exacerbation of Asthma Related to Aspirin Sensitivity</content>: DUEXIS is contraindicated in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin-sensitivity).  (<linkHtml href="#S5.10">5.10</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Serious Skin Reactions</content>: Discontinue DUEXIS at first appearance of skin rash or other signs of hypersensitivity. (<linkHtml href="#S5.11">5.11</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Premature Closure </content>
                              <content styleCode="underline">of </content>
                              <content styleCode="underline">the Fetal Ductus Arteriosus</content>: Avoid use in pregnant women starting at 30 weeks gestation.  (<linkHtml href="#S5.12">5.12</linkHtml>, <linkHtml href="#S8.1">8.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Hematologic Toxicity</content>: Monitor hemoglobin or hematocrit in patient with any signs or symptoms of anemia. (<linkHtml href="#S5.13">5.13</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="ad533b64-f3a2-434b-b308-0dab97d9d7e0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Cardiovascular Thrombotic Events</title>
                     <text>
                        <paragraph>Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI), and stroke, which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDS. The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease. However, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate. Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of             treatment. The increase in CV thrombotic risk has been observed most consistently at higher doses.</paragraph>
                        <paragraph>To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur.</paragraph>
                        <paragraph>There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID, such as ibuprofen, increases the risk of serious gastrointestinal GI events <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                     <component>
                        <section>
                           <id root="1f31abc2-b3ac-41bb-9dd9-4f02c447a32e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Status Post Coronary Artery Bypass Graft (CABG) Surgery</content>
                              </paragraph>
                              <paragraph>Two large, controlled, clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10â14 days following CABG surgery found an increased incidence of myocardial infarction and stroke. NSAIDs are contraindicated in the setting of CABG <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20190731"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="df855324-7f62-4c60-a13d-bcebf49e3db7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Post-MI Patients</content>
                              </paragraph>
                              <paragraph>Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs in the post-MI period were at increased risk of reinfarction, CV-related death, and all-cause mortality beginning in the first week of treatment. In this same cohort, the incidence of death in the first year post-MI was 20 per 100 person years in NSAID-treated patients compared to 12 per 100 person years in non-NSAID exposed patients. Although the absolute rate of death declined somewhat after the first year post-MI, the increased relative risk of death in NSAID users persisted over at least the next four years of follow-up.</paragraph>
                              <paragraph>Avoid the use of DUEXIS in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If DUEXIS is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.</paragraph>
                           </text>
                           <effectiveTime value="20190731"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="8d1b2c43-1186-4448-b5c5-ab76d7f612dc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Gastrointestinal Bleeding, Ulceration, and Perforation</title>
                     <text>
                        <paragraph>NSAIDs, including ibuprofen, cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDS. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occurred in approximately 1% of patients treated for 3-6 months, and in about 2%-4% of patients treated for one year. However, even short-term NSAID therapy is not without risk.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                     <component>
                        <section>
                           <id root="2cb2efa8-780e-43a9-ba67-2443ea498866"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Factors for GI Bleeding, Ulceration, and Perforation</content>
                              </paragraph>
                              <paragraph>Patients with a prior history of peptic ulcer disease and/or GI bleeding who used NSAIDs had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors. Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. Most postmarketing reports of fatal GI events occurred in elderly or debilitated patients. Additionally, patients with advanced liver disease and/or coagulopathy are at increased risk for GI bleeding.</paragraph>
                              <paragraph>NSAIDs should be given with care to patients with a history of inflammatory bowel disease (ulcerative colitis, Crohn's disease) as their condition may be exacerbated.</paragraph>
                           </text>
                           <effectiveTime value="20190731"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="26fe5418-af63-4609-bff0-4dad665b0e57"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Strategies to Minimize the GI Risks in NSAID-treated patients:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>Use the lowest effective dosage for the shortest possible duration.</item>
                                 <item>Avoid administration of more than one NSAID at a time.</item>
                                 <item>Avoid use in patients at higher risk unless benefits are expected to outweigh the increased risk of bleeding. For such patients, as well as those with active GI bleeding, consider alternate therapies other than NSAIDs.</item>
                                 <item>Remain alert for signs and symptoms of GI ulceration and bleeding during NSAID therapy.</item>
                                 <item>If a serious GI adverse event is suspected, promptly initiate evaluation and treatment, and discontinue DUEXIS until a serious GI adverse event is ruled out.</item>
                                 <item>In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, monitor patients more closely for evidence of GI bleeding <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</item>
                              </list>
                           </text>
                           <effectiveTime value="20190731"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="b4c53d84-8163-408d-9a9a-51ea88dc0b6c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Active Bleeding</title>
                     <text>
                        <paragraph>When active and clinically significant bleeding from any source occurs in patients receiving DUEXIS, the treatment should be withdrawn. Patients with initial hemoglobin values of 10 g or less who are to receive long-term therapy should have hemoglobin values determined periodically.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="e42b6617-eaa1-4159-a691-6f7eea2f5c33"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Hepatotoxicity</title>
                     <text>
                        <paragraph>Elevations of ALT or AST (three or more times the upper limit of normal [ULN]) have been reported in approximately 1% of NSAID-treated patients in clinical trials.  In addition, rare, sometimes fatal, cases of severe hepatic injury, including fulminant hepatitis, liver necrosis, and hepatic failure have been reported.</paragraph>
                        <paragraph>Elevations of ALT or AST (less than three times ULN) may occur in up to 15% of patients treated with NSAIDs including ibuprofen.</paragraph>
                        <paragraph>Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms). If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), discontinue DUEXIS immediately, and perform a clinical evaluation of the patient.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="3d73ffbd-e046-4c3a-b23a-3d9f64d23ee3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5	Hypertension</title>
                     <text>
                        <paragraph>NSAIDs, including DUEXIS, can lead to new onset of hypertension or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of CV events. Patients taking angiotensin converting enzyme (ACE) inhibitors, thiazide diuretics, or loop diuretics may have impaired response to these therapies when taking NSAIDs <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                        <paragraph>Monitor blood pressure (BP) during the initiation of NSAID treatment and throughout the course of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="2fd8fba4-9d23-4344-bd37-14cd4d9e3024"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6	Heart Failure and Edema</title>
                     <text>
                        <paragraph>The Coxib and traditional NSAID Trialists' Collaboration meta-analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for heart failure in COX-2 selective treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. In a Danish National Registry study of patients with heart failure, NSAID use increased the risk of MI, hospitalization for heart failure, and death.</paragraph>
                        <paragraph>Additionally, fluid retention and edema have been observed in some patients treated with NSAIDs. Use of ibuprofen may blunt the CV effects of several therapeutic agents used to treat these medical conditions (e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers [ARBs]) <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                        <paragraph>Avoid the use of DUEXIS in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If DUEXIS is used in patients with severe heart failure, monitor patients for signs and symptoms of worsening heart failure.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="291a7860-a244-450d-bae4-f406d6ca77a1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7	Renal Toxicity and Hyperkalemia</title>
                     <effectiveTime value="20190731"/>
                     <component>
                        <section>
                           <id root="11a2711d-2515-4ce8-8e7f-eee5b05345ca"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Renal Toxicity</content>
                              </paragraph>
                              <paragraph>Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy was usually followed by recovery to the pretreatment state.</paragraph>
                              <paragraph>No information is available from controlled clinical studies regarding the use of DUEXIS in patients with advanced renal disease. The renal effects of DUEXIS may hasten the progression of renal dysfunction in patients with pre-existing renal disease.</paragraph>
                              <paragraph>Correct volume status in dehydrated or hypovolemic patients prior to initiating DUEXIS.  Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of DUEXIS <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>. Avoid the use of DUEXIS in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal failure. If DUEXIS is used in patients with advanced renal disease, monitor patients for signs of worsening renal function.</paragraph>
                           </text>
                           <effectiveTime value="20190731"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="e6b5452f-1676-4813-aa8f-b69b1fe05d34"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Hyperkalemia</content>
                              </paragraph>
                              <paragraph>Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.</paragraph>
                           </text>
                           <effectiveTime value="20190731"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="66535326-1f32-423a-8e61-5fa45f1c7f3a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Anaphylactic Reactions</title>
                     <text>
                        <paragraph>Ibuprofen has been associated with anaphylactic reactions in patients with and without known hypersensitivity to ibuprofen and in patients with aspirin-sensitive asthma <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>,  <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>]</content>.</paragraph>
                        <paragraph>Seek emergency help if an anaphylactic reaction occurs.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.9">
                     <id root="8e7a2d38-bc2f-4ce5-9cbe-06f22bf66143"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9	Seizures</title>
                     <text>
                        <paragraph>Central nervous system (CNS) adverse effects including seizures, delirium, and coma have been reported with famotidine in patients with moderate (creatinine clearance &lt;50 mL/min) and severe renal insufficiency (creatinine clearance &lt;10 mL/min), and the dosage of the famotidine component in DUEXIS is fixed. Therefore, DUEXIS is not recommended in patients with creatinine clearance &lt; 50 mL/min.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.10">
                     <id root="3bf96695-9234-4d83-ae70-058b5512dc12"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10	Exacerbation of Asthma Related to Aspirin Sensitivity</title>
                     <text>
                        <paragraph>A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps; severe, potentially fatal bronchospasm; and/or intolerance to aspirin and other NSAIDs. Because cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, DUEXIS is contraindicated in patients with this form of aspirin sensitivity <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>. When DUEXIS is used in patients with preexisting asthma (without known aspirin sensitivity), monitor patients for changes in the signs and symptoms of asthma.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.11">
                     <id root="791498f2-516e-462c-9ed7-8d55af160aab"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11	Serious Skin Reactions</title>
                     <text>
                        <paragraph>NSAIDs, including ibuprofen, which is a component of DUEXIS tablets, can cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These serious events may occur without warning.  Inform patients about the signs and symptoms of serious skin reactions and to discontinue the use of DUEXIS at the first appearance of skin rash or any other sign of hypersensitivity. DUEXIS is contraindicated in patients with previous serious skin reactions to NSAIDs <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.12">
                     <id root="c918e0ac-a839-4b25-8424-f3fb8428b469"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.12	Premature Closure of Fetal Ductus Arteriosus</title>
                     <text>
                        <paragraph>Ibuprofen may cause premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs, including DUEXIS, in pregnant women starting at 30 weeks of gestation (third trimester) <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Population (8.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.13">
                     <id root="b5354083-31c0-4ac0-8ed6-42cb4b6589fe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.13 Hematologic Toxicity</title>
                     <text>
                        <paragraph>Anemia has occurred in NSAID-treated patients. This may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis. If a patient treated with DUEXIS has any signs or symptoms of anemia, monitor hemoglobin or hematocrit.</paragraph>
                        <paragraph>NSAIDs, including DUEXIS, may increase the risk of bleeding events. Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, and other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase the risk. Monitor these patients for signs of bleeding <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.14">
                     <id root="1432e47b-5cc1-43bd-a8ed-6f3ef7a0c993"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.14	Masking of Inflammation and Fever</title>
                     <text>
                        <paragraph>The pharmacological activity of DUEXIS in reducing inflammation, and possibly fever, may diminish the utility of diagnostic signs in detecting infections.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.15">
                     <id root="5ba52ad7-89f6-47a3-b7d7-ba5841f4e862"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.15 Laboratory Monitoring</title>
                     <text>
                        <paragraph>Because serious GI bleeding, hepatotoxicity, and renal injury can occur without warning symptoms or signs, consider monitoring patients on long-term NSAID treatment with a CBC and chemistry profile periodically <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#S5.4">5.4</linkHtml>, <linkHtml href="#S5.7">5.7)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.16">
                     <id root="fced16b9-53b3-4319-a116-85ee3d9295cc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.16	Concomitant NSAID Use</title>
                     <text>
                        <paragraph>DUEXIS contains ibuprofen as one of its active ingredients. It should not be used with other ibuprofen-containing products.</paragraph>
                        <paragraph>The concomitant use of NSAIDs, including aspirin, with DUEXIS may increase the risk of adverse reactions <content styleCode="italics">[see <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>, <linkHtml href="#S7">Drug Interactions (7)</linkHtml>, <linkHtml href="#S14">Clinical Studies (14)</linkHtml>
                           </content>]<content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.17">
                     <id root="7a7a0982-c7a4-4c1f-a6d9-43c51da469b2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.17	Aseptic Meningitis</title>
                     <text>
                        <paragraph>Aseptic meningitis with fever and coma has been observed on rare occasions in patients on ibuprofen, which is a component of DUEXIS. Although it is probably more likely to occur in patients with systemic lupus erythematosus (SLE) and related connective tissue diseases, it has been reported in patients who do not have an underlying chronic disease. If signs or symptoms of meningitis develop in a patient on DUEXIS, the possibility of its being related to ibuprofen should be considered.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.18">
                     <id root="fdc68e7a-eece-4e63-8d11-71715d48c25c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.18	Ophthalmological Effects</title>
                     <text>
                        <paragraph>Blurred and/or diminished vision, scotomata, and/or changes in color vision have been reported. If a patient develops such complaints while receiving DUEXIS, the drug should be discontinued, and the patient should have an ophthalmologic examination which includes central visual fields and color vision testing.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="0fd4130d-bc8f-4a25-8d7b-66303112b120"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious adverse reactions are discussed in greater detail in other sections of the labeling:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Cardiovascular Thrombotic Events <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>GI Bleeding, Ulceration, and Perforation <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Hepatotoxicity <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>Hypertension <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                     <item>Heart Failure and Edema <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>
                     </item>
                     <item>Renal Toxicity and Hyperkalemia <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>
                     </item>
                     <item>Anaphylactic Reactions <content styleCode="italics">[see <linkHtml href="#S5.8">Warnings and Precautions (5. 8)</linkHtml>]</content>
                     </item>
                     <item>Seizures <content styleCode="italics">[see <linkHtml href="#S5.9">Warnings and Precautions (5.9)</linkHtml>]</content>
                     </item>
                     <item>Serious Skin Reactions <content styleCode="italics">[see <linkHtml href="#S5.11">Warnings and Precautions (5.11)</linkHtml>]</content>
                     </item>
                     <item>Hematologic Toxicity <content styleCode="italics">[see <linkHtml href="#S5.13">Warnings and Precautions (5.13)</linkHtml>]</content>
                     </item>
                     <item>Aseptic Meningitis <content styleCode="italics">[see <linkHtml href="#S5.17">Warnings and Precautions (5.17)</linkHtml>]</content>
                     </item>
                     <item>Ophthalmological Effects <content styleCode="italics">[see <linkHtml href="#S5.18">Warnings and Precautions (5.18)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20190731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (â¥1% and greater than ibuprofen alone) are nausea, diarrhea, constipation, upper abdominal pain, and headache. (<linkHtml href="#S6.1">6.1</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Horizon at (1-866-479-6742) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</content>
                           <content styleCode="bold italics">.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="ee319b76-e41d-45a9-8d31-c45388348694"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1	Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The safety of DUEXIS was evaluated in 1022 patients in controlled clinical studies, including 508 patients treated for at least 6 months and 107 patients treated for approximately 1 year. Patients treated with DUEXIS ranged in age from 39 to 80 years (median age 55 years), with 67% female, 79% Caucasian, 18% African-American, and 3% other races. Two randomized, active-controlled clinical studies (Study 301 and Study 303) were conducted for the reduction of the risk of development of ibuprofen-associated, upper gastrointestinal ulcers in patients who required use of ibuprofen, which included 1022 patients on DUEXIS and 511 patients on ibuprofen alone. Approximately 15% of patients were on low- dose aspirin. Patients were assigned randomly, in a 2:1 ratio, to treatment with either DUEXIS or ibuprofen 800 mg three times a day for 24 consecutive weeks.</paragraph>
                        <paragraph>Three serious cases of acute renal failure were observed in patients treated with DUEXIS in the two controlled clinical trials. All three patients recovered to baseline levels after discontinuation of DUEXIS. Additionally, increases in serum creatinine were observed in both treatment arms in the two clinical studies. Many of these patients were taking concomitant diuretics and/or angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers. There were patients with a normal baseline serum creatinine level who developed abnormal values in the controlled trials as presented in Table 1.</paragraph>
                        <table width="90%">
                           <caption>Table 1:  Shift Table of Serum Creatinine, Normal<footnote ID="foot11">serum creatinine normal range is 0.5 â 1.4 mg/dL or 44-124 micromol/L</footnote> to Abnormal<footnote ID="foot12">serum creatinine &gt;1.4 mg/dL</footnote> in Controlled Studies</caption>
                           <col width="10%" align="center" valign="top"/>
                           <col width="18%" align="center" valign="top"/>
                           <col width="18%" align="center" valign="top"/>
                           <col width="18%" align="center" valign="top"/>
                           <col width="18%" align="center" valign="top"/>
                           <col width="18%" align="center" valign="top"/>
                           <thead>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule"/>
                                 <th styleCode="Rrule" colspan="2">Study 301</th>
                                 <th styleCode="Rrule" colspan="2">Study 303</th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule">Baseline</th>
                                 <th styleCode="Rrule">Post-Baseline<footnote ID="foot13">At any point after baseline level</footnote>
                                 </th>
                                 <th styleCode="Rrule">DUEXIS<br/>N=414<br/>% (n)</th>
                                 <th styleCode="Rrule">Ibuprofen<br/>N=207<br/>% (n)</th>
                                 <th styleCode="Rrule">DUEXIS<br/>N=598<br/>% (n)</th>
                                 <th styleCode="Rrule">Ibuprofen<br/>N=296<br/>% (n)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule">Normal<footnoteRef IDREF="foot11"/>
                                 </td>
                                 <td styleCode="Rrule">Abnormal<footnoteRef IDREF="foot12"/>
                                 </td>
                                 <td styleCode="Rrule">4% (17)</td>
                                 <td styleCode="Rrule">2% (4)</td>
                                 <td styleCode="Rrule">2%(15)</td>
                                 <td styleCode="Rrule">4% (12)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20190731"/>
                     <component>
                        <section>
                           <id root="45d754df-79cb-4d2b-b7ea-a2aedb6e8443"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Most Commonly Reported Adverse Reactions</content>
                              </paragraph>
                              <paragraph>The most common adverse reactions (â¥2%), from pooled data from the two controlled studies are presented in Table 2.</paragraph>
                              <table width="75%">
                                 <caption>Table 2:  Incidence of Adverse Reactions in Controlled Studies</caption>
                                 <col width="60%" align="left" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule" rowspan="2"/>
                                       <th styleCode="Rrule Botrule">DUEXIS<br/>N=1022</th>
                                       <th styleCode="Rrule Botrule">Ibuprofen<br/>N=511</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Rrule" align="center">%</th>
                                       <th styleCode="Rrule">%</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Blood and lymphatic system disorders</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Anemia</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Gastrointestinal disorders</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Nausea</td>
                                       <td styleCode="Rrule">6</td>
                                       <td styleCode="Rrule">5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Dyspepsia</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Diarrhea</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Constipation</td>
                                       <td styleCode="Rrule">4</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Abdominal pain upper</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Gastroesophageal reflux disease</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Vomiting</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Stomach discomfort</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Abdominal pain</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">General disorders and administration site conditions</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Edema peripheral</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Infections and infestations</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Upper respiratory tract infection</td>
                                       <td styleCode="Rrule">4</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Nasopharyngitis</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Sinusitis</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Bronchitis</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Urinary tract infection</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Influenza</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Musculoskeletal and connective tissue disorders</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Arthralgia</td>
                                       <td styleCode="Rrule">1</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Back pain</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Nervous system disorders</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Headache</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Respiratory, thoracic and mediastinal disorders</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Cough</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Pharyngolaryngeal pain</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Vascular disorders</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â Hypertension</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>In controlled clinical studies, the discontinuation rate due to adverse events for patients receiving DUEXIS and ibuprofen alone were similar. The most common adverse reactions leading to discontinuation from DUEXIS therapy were nausea (0.9%) and upper abdominal pain (0.9%).</paragraph>
                              <paragraph>There were no differences in types of related adverse reactions seen during maintenance treatment up to 12 months compared to short-term treatment.</paragraph>
                           </text>
                           <effectiveTime value="20190731"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="1983f262-bd75-4c07-890a-b635946286d3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2	Postmarketing Experience</title>
                     <effectiveTime value="20190731"/>
                     <component>
                        <section>
                           <id root="b386bc70-92a0-474b-8bbd-53db4be99a51"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Ibuprofen</content>
                              </paragraph>
                              <paragraph>The following adverse reactions have been identified during post-approval use of ibuprofen. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These reports are listed below by body system:</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Cardiac disorders</content>: myocardial infarction</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Gastrointestinal disorders</content>: nausea, vomiting, diarrhea, abdominal pain</paragraph>
                              <paragraph>
                                 <content styleCode="italics">General disorders and administration site conditions</content>: pyrexia, pain, fatigue, asthenia, chest pain, drug ineffective, edema peripheral</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Musculoskeletal and connective tissue disorders</content>: arthralgia</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Nervous system disorders</content>: headache, dizziness</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Psychiatric disorders</content>: depression, anxiety</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Renal and urinary disorders</content>: renal failure acute</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Respiratory, thoracic, and mediastinal disorders</content>: dyspnea</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Vascular disorders</content>: hypertension</paragraph>
                           </text>
                           <effectiveTime value="20190731"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="e826d5f3-1a2d-4b7d-b313-3d5ad366fc97"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Famotidine</content>
                              </paragraph>
                              <paragraph>The following adverse reactions have been identified during post-approval use of famotidine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These reports are listed below by body system:</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Blood and lymphatic system disorders</content>: anemia, thrombocytopenia </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Gastrointestinal disorders</content>: nausea, diarrhea, vomiting, abdominal pain</paragraph>
                              <paragraph>
                                 <content styleCode="italics">General disorders and administration site conditions</content>: pyrexia, condition aggravated, asthenia, drug ineffective, chest pain, fatigue, pain, edema peripheral</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Hepatobiliary disorders</content>: hepatic function abnormal </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Infections and infestations</content>: pneumonia, sepsis</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Investigations</content>: platelet count decreased, aspartate aminotransferase increased, alanine aminotransferase increased, hemoglobin decreased</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Metabolism and nutrition disorders</content>: decreased appetite</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Nervous system disorders</content>: dizziness, headache</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Respiratory, thoracic, and mediastinal disorders</content>: dyspnea</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Vascular disorders</content>: hypotension</paragraph>
                           </text>
                           <effectiveTime value="20190731"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="f07369f5-94b3-4732-894a-3193e0a26c95"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>See <linkHtml href="#Table3">Table 3</linkHtml> for clinically significant drug interactions with ibuprofen.</paragraph>
                  <table width="85%" ID="Table3">
                     <caption>Table 3:	Clinically Significant Drug Interactions with Ibuprofen and Famotidine</caption>
                     <col width="30%" align="left" valign="top"/>
                     <col width="70%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Rrule Botrule" colspan="2">
                              <content styleCode="bold">Drugs That Interfere with Hemostasis</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="right" valign="middle">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="disc">
                                 <item>Ibuprofen and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of ibuprofen and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone.</item>
                                 <item>Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="right" valign="middle">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">Monitor patients with concomitant use of DUEXIS with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding <content styleCode="italics">[see <linkHtml href="#S5.15">Warnings and Precautions (5.15)</linkHtml>]</content>.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">Aspirin</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" align="right" valign="middle">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">Pharmacodynamic (PD) studies have demonstrated interference with the antiplatelet activity of aspirin when ibuprofen 400 mg, given three times daily, is administered with enteric-coated low-dose aspirin. The interaction exists even following a once-daily regimen of ibuprofen 400 mg, particularly when ibuprofen is dosed prior to aspirin. The interaction is alleviated if <content styleCode="italics">immediate-release</content> low-dose aspirin is dosed at least 2 hours prior to a once-daily regimen of ibuprofen; however, this finding cannot be extended to enteric-coated low-dose aspirin <content styleCode="italics">[see <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>].</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="right" valign="middle"/>
                           <td styleCode="Rrule">Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" align="right" valign="middle">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">Because there may be an increased risk of cardiovascular events due to the interference of ibuprofen with the antiplatelet effect of aspirin, for patients taking low-dose aspirin for cardioprotection who require analgesics, consider use of an NSAID that does not interfere with the antiplatelet effect of aspirin, or non-NSAID analgesics, where appropriate.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="right" valign="middle"/>
                           <td styleCode="Rrule">Concomitant use of DUEXIS and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.<br/>DUEXIS is not a substitute for low dose aspirin for cardiovascular protection.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-blockers</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="right" valign="middle">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="disc">
                                 <item>NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol).</item>
                                 <item>In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible<content styleCode="italics">.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="right" valign="middle">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="disc">
                                 <item> During concomitant use of DUEXIS and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained.</item>
                                 <item>During concomitant use of DUEXIS and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted or have impaired renal function, monitor for signs of worsening renal function <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">Diuretics</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="right" valign="middle">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="right" valign="middle">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">During concomitant use of DUEXIS with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">Digoxin</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="right" valign="middle">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">The concomitant use of ibuprofen with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="right" valign="middle">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">During concomitant use of DUEXIS and digoxin, monitor serum digoxin levels.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">Lithium</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="right" valign="middle">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">NSAIDs have produced elevations of plasma lithium levels and reductions in renal lithium clearance. The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="right" valign="middle">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">During concomitant use of DUEXIS and lithium, monitor patients for signs of lithium toxicity.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">Methotrexate</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="right" valign="middle">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction).</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="right" valign="middle">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">During concomitant use of DUEXIS and methotrexate, monitor patients for methotrexate toxicity.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">Cyclosporine</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="right" valign="middle">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">Concomitant use of ibuprofen and cyclosporine may increase cyclosporine's nephrotoxicity.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="right" valign="middle">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">During concomitant use of DUEXIS and cyclosporine, monitor patients for signs of worsening renal function.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">NSAIDs and Salicylates</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="right" valign="middle">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">Concomitant use of ibuprofen with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="right" valign="middle">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">The concomitant use of DUEXIS with other NSAIDs or salicylates is not recommended.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">Pemetrexed</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="right" valign="middle">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Rrule">Concomitant use of ibuprofen and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information).</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="right" valign="middle">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Rrule">During concomitant use of DUEXIS and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity.<br/>NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed.<br/>In the absence of data regarding potential interaction between permetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">Drugs Dependent on Gastric pH for Absorption</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="right" valign="top">
                              <content styleCode="italics">Clinical Impact</content>
                           </td>
                           <td styleCode="Rrule">Because famotidine lowers intra-gastric acidity, this may result in reduced absorption and loss of efficacy of concomitant drugs.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="right" valign="top">
                              <content styleCode="italics">Intervention</content>
                           </td>
                           <td styleCode="Rrule">Concomitant administration of DUEXIS is not recommended with dasatinib, delavirdine mesylate, cefditoren, and fosamprenavir.<br/>For administration instructions of other drugs whose absorption is dependent on gastric pH, refer to their prescribing information (e.g., atazanavir, erlotinib, ketoconazole, itraconazole, nilotinib, ledipasvir/sofosbuvir, and rilpivirine).</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">Tizanidine (CYP1A2 Substrate)</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="right" valign="top">
                              <content styleCode="italics">Clinical Impact</content>
                           </td>
                           <td styleCode="Rrule">Famotidine is considered a weak CYP1A2 inhibitor and may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" align="right" valign="top">
                              <content styleCode="italics">Intervention</content>
                           </td>
                           <td styleCode="Rrule">Avoid concomitant use with DUEXIS.<br/>If concomitant use is necessary, monitor for hypotension, bradycardia or excessive drowsiness.<br/>Refer to the full prescribing information for tizanidine.</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20190731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>See full prescribing information for a list of clinically important drug interactions. (<linkHtml href="#S7">7</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="363808d3-e3ba-4ab9-ad1a-f15558240fd1"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20190731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="underline">Pregnancy</content>: Use of NSAIDs during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs in pregnant women starting at 30 weeks gestation. (<linkHtml href="#S5.12">5.12</linkHtml>, <linkHtml href="#S8.1">8.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Females and Males of Reproductive Potential</content>: NSAIDs are associated with reversible infertility. Consider withdrawal of DUEXIS in women who have difficulties conceiving. (<linkHtml href="#S8.3">8.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="23ba7f9a-ea59-4db7-ac06-55f5618e6094"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20190731"/>
                     <component>
                        <section>
                           <id root="072cb648-63c3-4a67-b5c6-23eababab12b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Use of NSAIDs, including DUEXIS, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs, including DUEXIS, in pregnant women starting at 30 weeks of gestation (third trimester). There are no adequate and well-controlled studies of DUEXIS in pregnant women.</paragraph>
                           </text>
                           <effectiveTime value="20190731"/>
                           <component>
                              <section>
                                 <id root="eb11e455-5c90-4275-93ca-179f7c1c1a2d"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Ibuprofen</paragraph>
                                    <paragraph>There are no adequate and well-controlled studies of ibuprofen in pregnant women. Data from observational studies regarding potential embryofetal risks of NSAID use in women in the first or second trimesters of pregnancy are inconclusive.  In published animal reproduction studies, there were no clear developmental effects at doses up to 0.4- times the maximum recommended human dose (MRHD) in the rabbit and 0.5-times in the MRHD rat when dosed throughout gestation. In contrast, an increase in membranous ventricular septal defects was reported in rats treated on Gestation Days 9 &amp; 10 with 0.8-times the MRHD.  Based on animal data, prostaglandins have been shown to have an important role in endometrial vascular permeability, blastocyst implantation, and decidualization. In animal studies, administration of prostaglandin synthesis inhibitors such as ibuprofen, resulted in increased pre- and post-implantation loss. Advise a pregnant woman of the potential risk to a fetus.</paragraph>
                                 </text>
                                 <effectiveTime value="20190731"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="8e0cc149-e1ac-47d8-89ba-8b033497f837"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Famotidine</paragraph>
                                    <paragraph>Limited published data do not report an increased risk of congenital malformations or other adverse pregnancy effects with use of H2- receptor antagonists, including DUEXIS, during pregnancy; however, these data are insufficient to adequately determine a drug-associated risk. Reproductive studies with famotidine have been performed in rats and rabbits at oral doses of up to 2000 and 500 mg/kg/day (approximately 243 and 122 times the recommended human dose, respectively, based on body surface area) and in both species at intravenous (I.V.) doses of up to 200 mg/kg/day, and have revealed no significant evidence of impaired fertility or harm to the fetus due to famotidine.</paragraph>
                                    <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the general U.S. population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</paragraph>
                                 </text>
                                 <effectiveTime value="20190731"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="5abe4694-92f4-4fbc-9a7a-45c3845085fc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20190731"/>
                           <component>
                              <section>
                                 <id root="7f53d314-4b47-4305-916d-9191779b154e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Labor or Delivery</content>
                                    </paragraph>
                                    <paragraph>There are no studies on the effects of DUEXIS during labor or delivery.  In animal studies, NSAIDs, including ibuprofen, inhibit prostaglandin synthesis, cause delayed parturition, and increase the incidence of stillbirth.</paragraph>
                                 </text>
                                 <effectiveTime value="20190731"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="f0883c2b-6c1a-4f24-87b4-2eec46fc0a9c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20190731"/>
                           <component>
                              <section>
                                 <id root="dd27eb66-a0e6-4675-8e24-3bed38465dfe"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Human Data</content>
                                    </paragraph>
                                    <paragraph>When used to delay preterm labor, inhibitors of prostaglandin synthesis, including NSAIDs such ibuprofen, may increase the risk of neonatal complications such as necrotizing enterocolitis, patent ductus arteriosus and intracranial hemorrhage. Ibuprofen treatment given in late pregnancy to delay parturition has been associated with persistent pulmonary hypertension, renal dysfunction and abnormal prostaglandin E levels in preterm infants.</paragraph>
                                 </text>
                                 <effectiveTime value="20190731"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="111d421b-cfea-43fe-94d6-81935d6e254b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Animal reproduction studies have not been conducted with DUEXIS. </paragraph>
                                 </text>
                                 <effectiveTime value="20190731"/>
                                 <component>
                                    <section>
                                       <id root="c6d2f6f9-9baa-42c8-8243-d7966005835f"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>Ibuprofen</paragraph>
                                          <paragraph>In a published study, female rabbits given 7.5, 20, or 60 mg/kg ibuprofen (0.04, 0.12, or 0.36-times the maximum recommended human daily dose of 3200 mg of ibuprofen based on body surface area) from Gestation Days 1 to 29, no clear treatment-related adverse developmental effects were noted. Doses of 20 and 60 mg/kg were associated with significant maternal toxicity (stomach ulcers, gastric lesions). In the same publication, female rats were administered 7.5, 20, 60, 180 mg/kg ibuprofen (0.02, 0.06, 0.18, 0.54-times the maximum daily dose) did not result in clear adverse developmental effects. Maternal toxicity (gastrointestinal lesions) was noted at 20 mg/kg and above.</paragraph>
                                          <paragraph>In a published study, rats were orally dosed with 300 mg/kg ibuprofen (0.912-times the maximum human daily dose of 3200 mg based on body surface area) during Gestation Days 9 and 10 (critical time points for heart development in rats). Ibuprofen treatment resulted in an increase in the incidence of membranous ventricular septal defects. This dose was associated with significant maternal toxicity including gastrointestinal toxicity. One incidence each of a membranous ventricular septal defect and gastroschisis was noted in fetuses from rabbits treated with 500 mg/kg (3-times the maximum human daily dose) from Gestation Day 9-11.</paragraph>
                                       </text>
                                       <effectiveTime value="20190731"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="86f1f9a8-e02c-487f-a6c9-20eda9c474f9"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>Famotidine</paragraph>
                                          <paragraph>Reproductive studies with famotidine have been performed in rats and rabbits at oral doses of up to 2000 and 500 mg/kg/day (approximately 243 and 122 times the recommended human dose of 80 mg per day, respectively, based on body surface area) and in both species at intravenous doses of up to 200 mg/kg/day (about 24 and 49 times the recommended human dose of 80 mg per day, respectively, based on body surface area), and have revealed no significant evidence of harm to the fetus due to famotidine. While no direct fetotoxic effects have been observed, sporadic abortions occurring only in mothers displaying marked decreased food intake were seen in some rabbits at oral doses of 200 mg/kg/day (approximately 49 times the recommended human dose of 80 mg per day, respectively, based on body surface area) or higher. Animal reproduction studies are not always predictive of human response.</paragraph>
                                       </text>
                                       <effectiveTime value="20190731"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="132a65db-3087-4014-bb28-82fd4f5d5ceb"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20190731"/>
                     <component>
                        <section>
                           <id root="1b9d6513-f8a2-4d49-bb1c-015706f0487e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>No studies have been conducted with the use of DUEXIS in lactating women.  Limited data from published literature report famotidine is present in human milk in low amounts. Published literature also reports the presence of ibuprofen in human milk in low amounts.  No information is available on the effects of famotidine or ibuprofen on milk production or on a breastfed infant. Famotidine is present in the milk of lactating rats <content styleCode="italics">(see <linkHtml href="#Data">Data</linkHtml>)</content>.  The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for DUEXIS and any potential adverse effects on the breastfed infant from DUEXIS or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20190731"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Data">
                           <id root="25ee3327-1136-45bc-a0fd-c0eceffe9cd4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                              <paragraph>Transient growth depression was observed in young rats suckling from mothers treated with maternotoxic doses of at least 300 times the usual human dose of famotidine.</paragraph>
                           </text>
                           <effectiveTime value="20190731"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="560b5317-96c0-45b2-a05e-c1ab7ac91623"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3	Females and Males of Reproductive Potential</title>
                     <effectiveTime value="20190731"/>
                     <component>
                        <section>
                           <id root="7a2055e5-cd3d-4f03-b0a4-6ccbe400558c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Infertility</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20190731"/>
                           <component>
                              <section>
                                 <id root="c9e7dbfa-6264-4019-a0b3-e247ba8ae2f7"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Females</content>
                                    </paragraph>
                                    <paragraph>Based on the mechanism of action, the use of prostaglandin-mediated NSAIDs, including DUEXIS, may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women.  Published animal studies have shown that administration of prostaglandin synthesis inhibitors has the potential to disrupt prostaglandin- mediated follicular rupture required for ovulation. Small studies in women treated with NSAIDs have also shown a reversible delay in ovulation. Consider withdrawal of NSAIDs, including DUEXIS, in women who have difficulties conceiving or who are undergoing investigation of infertility.</paragraph>
                                 </text>
                                 <effectiveTime value="20190731"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="0d8bb627-752b-4c60-b42a-0e08807c52e1"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of DUEXIS in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="2ed3dc67-c7cd-42d2-945c-0c6b2d027151"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Elderly  patients,  compared  to  younger  patients,  are  at  greater  risk  for  NSAID-associated  serious  cardiovascular, gastrointestinal, and/or renal adverse reactions. If the anticipated benefit for the elderly patient outweighs these potential risks, start dosing at the low end of the dosing range, and monitor patients for adverse effects <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>, <linkHtml href="#S5.4">5.4</linkHtml>, <linkHtml href="#S5.7">5.7</linkHtml>, <linkHtml href="#S5.15">5.15)</linkHtml>]</content>.</paragraph>
                        <paragraph>The clinical trials primarily enrolled patients less than 65 years of age. Of the 1022 patients in clinical studies of DUEXIS, 18% (249 patients) were 65 years of age or older.  Efficacy results in patients who are greater than or equal to 65 years of age are summarized in the CLINICAL STUDIES section <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Famotidine is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and adjusting dose interval, and it may be useful to monitor renal function <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="927c8415-ba96-415b-a2ee-827ded06d844"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6	Renal Insufficiency</title>
                     <text>
                        <paragraph>In adult patients with renal insufficiency (creatinine clearance &lt; 50 mL/min), the elimination half-life of famotidine is increased. Since CNS adverse effects have been reported in patients with creatinine clearance &lt; 50 mL/min and the dosage of the famotidine component in DUEXIS is fixed, DUEXIS is not recommended in these patients <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="c61c4633-ef40-4580-be54-5aaa6d6ecd05"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Symptoms following acute NSAID overdosages have been typically limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which have been generally reversible with supportive care. Gastrointestinal bleeding has occurred. Hypertension, acute renal failure, respiratory depression, and coma have occurred, but were rare <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>, <linkHtml href="#S5.5">5.5</linkHtml>, <linkHtml href="#S5.7">5.7</linkHtml>, <linkHtml href="#S5.9">5.9)</linkHtml>]</content>.</paragraph>
                  <paragraph>No data are available with regard to overdose of DUEXIS.  Findings related to the individual active substances are listed below.</paragraph>
               </text>
               <effectiveTime value="20190731"/>
               <component>
                  <section>
                     <id root="8c20eadc-af86-474d-916b-affedeedb54c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Ibuprofen</content>
                        </paragraph>
                        <paragraph>Approximately 1 1/2 hours after the reported ingestion of from 7 to 10 ibuprofen tablets (400 mg), a 19-month-old child weighing 12 kg was seen in the hospital emergency room, apneic and cyanotic, responding only to painful stimuli.  This type of stimulus, however, was sufficient to induce respiration. Oxygen and parenteral fluids were given; a greenish- yellow fluid was aspirated from the stomach with no evidence to indicate the presence of ibuprofen. Two hours after ingestion the child's condition seemed stable; she still responded only to painful stimuli and continued to have periods of apnea lasting from 5 to 10 seconds. She was admitted to intensive care and sodium bicarbonate was administered as well as infusions of dextrose and normal saline.  By 4 hours post-ingestion she could be aroused easily, sit by herself, and respond to spoken commands.  Blood level of ibuprofen was 102.9 Âµg/mL approximately 8.5 hours after accidental ingestion.  At 12 hours she appeared to be completely recovered.</paragraph>
                        <paragraph>In two other reported cases where children (each weighing approximately 10 kg) accidentally, acutely ingested approximately 120 mg/kg, there were no signs of acute intoxication or late sequelae.  Blood level in one child 90 minutes after ingestion was 700 Âµg/mL â about 10 times the peak levels seen in absorption-excretion studies.</paragraph>
                        <paragraph>A 19-year-old male who had taken 8,000 mg of ibuprofen over a period of a few hours complained of dizziness, and nystagmus was noted. After hospitalization, parenteral hydration and 3 days bed rest, he recovered with no reported sequelae.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="d4503ea3-c21d-4d17-ad4a-837fdbd8773c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Famotidine</content>
                        </paragraph>
                        <paragraph>The adverse reactions in overdose cases are similar to the adverse reactions encountered in normal clinical experience. Oral doses of up to 640 mg/day have been given to adult patients with pathological hypersecretory conditions with no serious adverse effects.</paragraph>
                        <paragraph>Manage patients with symptomatic and supportive care following an NSAID overdosage, including DUEXIUS overdose. There are no specific antidotes. Consider emesis and/or activated charcoal (60 to 100 grams in adults, 1 to 2 grams per kg of body weight in pediatric patients) and/or osmotic cathartic in symptomatic patients seen within four hours of ingestion or in patients with a large overdosage (5 to 10 times the recommended dose). Forced diuresis, alkalinization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.</paragraph>
                        <paragraph>If over-exposure occurs, call your poison control center at 1-800-222-1222 for current information on the management of poisoning or over-exposure.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="f4427237-53d8-4981-99f9-82c2c5497c86"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>DUEXIS (ibuprofen and famotidine) is supplied as a tablet for oral administration which combines the nonsteroidal anti- inflammatory drug, ibuprofen, and the histamine H<sub>2</sub>-receptor antagonist, famotidine.</paragraph>
                  <paragraph>Ibuprofen is (Â±)-2-(<content styleCode="italics">p-</content>isobutylphenyl)propionic acid. Its chemical formula is C<sub>13</sub>H<sub>18</sub>O<sub>2</sub> and molecular weight is 206.28. Ibuprofen is a white powder that is very slightly soluble in water (&lt;1 mg/mL) and readily soluble in organic solvents such as ethanol and acetone. Its structural formula is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>Famotidine is <content styleCode="italics">N'-</content>(aminosulfonyl)-3-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]propanimidamide. Its chemical formula is C<sub>8</sub>H<sub>15</sub>N<sub>7</sub>O<sub>2</sub>S<sub>3</sub> and molecular weight is 337.45. Famotidine is a white to pale yellow crystalline compound that is freely soluble in glacial acetic acid, slightly soluble in methanol, very slightly soluble in water, and practically insoluble in ethanol.  Its structural formula is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM2"/>
                  </paragraph>
                  <paragraph>Each DUEXIS tablet contains ibuprofen, USP (800 mg) and famotidine, USP (26.6 mg).  The inactive ingredients in DUEXIS include: microcrystalline cellulose, anhydrous lactose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, purified water, povidone, titanium dioxide, polyethylene glycol, polysorbate 80, polyvinyl alcohol, hypromellose, talc, FD&amp;C Blue #2/Indigo Carmine Aluminum Lake, and FD&amp;C Blue #1/Brilliant Blue FCF Aluminum Lake.</paragraph>
               </text>
               <effectiveTime value="20190731"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="duexis-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM2">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="duexis-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="325743b6-b650-4385-af73-1e0735602ab4"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20190731"/>
               <component>
                  <section ID="S12.1">
                     <id root="48a8bf67-ab13-4d4f-b20b-7661059cd9ae"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>DUEXIS is a fixed-combination tablet of ibuprofen and famotidine. The ibuprofen component has analgesic, anti- inflammatory, and antipyretic properties. The mechanism of action of the ibuprofen component of DUEXIS, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).</paragraph>
                        <paragraph>Ibuprofen is a potent inhibitor of prostaglandin synthesis in vitro.  Ibuprofen concentrations reached during therapy have produced in vivo effects.  Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation.  Because ibuprofen is an inhibitor of prostaglandin synthesis, its mode of action may be due to an increase of prostaglandins in peripheral tissues.</paragraph>
                        <paragraph>Famotidine is a competitive inhibitor of histamine H<sub>2</sub>-receptors. The primary clinically important pharmacologic activity of famotidine is inhibition of gastric secretion.  Both the acid concentration and volume of gastric secretion are suppressed by famotidine, while changes in pepsin secretion are proportional to volume output.</paragraph>
                        <paragraph>Systemic effects of famotidine in the CNS, cardiovascular, respiratory, or endocrine systems were not noted in clinical pharmacology studies. Also, no antiandrogenic effects were noted. Serum hormone levels, including prolactin, cortisol, thyroxine (T<sub>4</sub>), and testosterone, were not altered after treatment with famotidine.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="9981288b-8f01-49f1-a381-9d9430528166"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2	Pharmacodynamics</title>
                     <text>
                        <paragraph>In a healthy volunteer study, ibuprofen 400 mg given once daily, administered 2 hours prior to immediate-release aspirin (81 mg) for 6 days, showed an interaction with the antiplatelet activity of aspirin as measured by % serum thromboxane B2 (TxB2) inhibition at 24 hours following the day-6 aspirin dose [53%]. An interaction was still observed, but minimized, when ibuprofen 400 mg given once-daily was administered as early as 8 hours prior to the immediate-release aspirin dose [90.7%]. However, there was no interaction with the antiplatelet activity of aspirin when ibuprofen 400 mg, given once daily, was administered 2 hours after (but not concomitantly, 15 min, or 30 min after) the immediate-release aspirin dose [99.2%].</paragraph>
                        <paragraph>In another study, where immediate-release aspirin 81 mg was administered once daily with ibuprofen 400 mg given three times daily (1, 7, and 13 hours post-aspirin dose) for 10 consecutive days, the mean % serum thromboxane B2 (TxB2) inhibition suggested no interaction with the antiplatelet activity of aspirin [98.3%]. However, there were individual subjects with serum TxB2 inhibition below 95%, with the lowest being 90.2%.</paragraph>
                        <paragraph>When a similarly designed study was conducted with enteric-coated aspirin, where healthy subjects were administered enteric-coated aspirin 81 mg once daily for 6 days and ibuprofen 400 mg three times daily (2, 7, and 12 h post-aspirin dose) for 6 days, there was an interaction with the antiplatelet activity at 24 hours following the day-6 aspirin dose [67%] <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="762e7474-ec91-42eb-83d6-d883fa243027"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20190731"/>
                     <component>
                        <section>
                           <id root="2c756715-1921-444c-8ecc-20e2b87e7025"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>Ibuprofen and famotidine are rapidly absorbed after a single dose administration of DUEXIS.  Mean C<sub>max</sub> values for ibuprofen are 45 Âµg/mL and are reached approximately 1.9 hours after oral administration of DUEXIS. The C<sub>max</sub> and AUC<sub>0-24hours</sub> values for the 800 mg of ibuprofen contained in a DUEXIS tablet are bioequivalent to the values for 800 mg of ibuprofen administered alone. C<sub>max</sub> values for famotidine were 61 ng/mL and are reached at approximately 2 hours after oral administration of DUEXIS.</paragraph>
                              <paragraph>A high-fat meal reduced famotidine C<sub>max</sub> and AUC by approximately by 15% and 11%, respectively, and reduced ibuprofen AUC by approximately 14% but did not change C<sub>max</sub>. Food delayed famotidine T<sub>max</sub> and ibuprofen T<sub>max</sub> by approximately 1 hour and 0.2 hour, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20190731"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="de0be520-8bd4-49fe-89db-edd9a523313d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>Ibuprofen is extensively bound to plasma proteins.</paragraph>
                              <paragraph>Fifteen to 20% of famotidine in plasma is protein bound.</paragraph>
                           </text>
                           <effectiveTime value="20190731"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="51d57660-b08a-495f-9241-454789679f01"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20190731"/>
                           <component>
                              <section>
                                 <id root="68dfa724-da2b-48c6-94d9-d6150eedc55a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>The only metabolite of famotidine identified in man is the S-oxide.</paragraph>
                                 </text>
                                 <effectiveTime value="20190731"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="a74c4ebd-f58d-4dad-aa9c-1a1215c7bf86"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                    <paragraph>Ibuprofen is eliminated from the systemic circulation with a mean half-life (t<sub>1/2</sub>) value of 2 hours following administration of a single dose of DUEXIS.</paragraph>
                                    <paragraph>Ibuprofen is rapidly metabolized and eliminated in the urine. The excretion of ibuprofen is virtually complete 24 hours after the last dose.</paragraph>
                                    <paragraph>Studies have shown that following ingestion of the drug, 45% to 79% of the dose was recovered in the urine within 24 hours as metabolite A (25%), (+)-2-[p-(2-hydroxymethyl-propyl) phenyl] propionic acid and metabolite B (37%), (+)- 2-[p-(2-carboxypropyl)phenyl] propionic acid; the percentages of free and conjugated ibuprofen were approximately 1% and 14%, respectively.</paragraph>
                                    <paragraph>Famotidine is eliminated from the systemic circulation with a mean t<sub>1/2</sub> value of 4 hours following administration of a single dose of DUEXIS.</paragraph>
                                    <paragraph>Famotidine is eliminated by renal (65-70%) and metabolic (30-35%) routes.  Renal clearance is 250-450 mL/min, indicating some tubular excretion. Twenty-five to 30% of an oral dose and 65-70% of an intravenous dose are recovered in the urine as unchanged compound.</paragraph>
                                 </text>
                                 <effectiveTime value="20190731"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="800de4c6-5fe3-4a4c-8ac3-2c5deb68540b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20190731"/>
                           <component>
                              <section>
                                 <id root="aef5f978-f2ac-45f6-8dc9-4008bf21acba"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Pediatric</content>s: The pharmacokinetics of ibuprofen or famotidine after administration of DUEXIS have not been evaluated in a pediatric population considering the doses of ibuprofen and famotidine in DUEXIS are targeted for use in an adult population.</paragraph>
                                 </text>
                                 <effectiveTime value="20190731"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="ad536df8-62a0-4009-8a91-fa22f121e78d"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Hepatic impairment</content>: The effects of hepatic impairment on the pharmacokinetics of ibuprofen or famotidine after administration of DUEXIS have not been evaluated <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20190731"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="076fb550-0225-4a5b-9ef0-9fee061cd554"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Renal impairment</content>: There is a close relationship between creatinine clearance values and the elimination t<sub>1/2</sub> of famotidine, which is a component of DUEXIS tablets.  In patients with creatinine clearance &lt;50 mL/min, the elimination t<sub>1/2</sub> of famotidine is increased and may exceed 20 hours. Therefore, DUEXIS is not recommended in patients with creatinine clearance &lt; 50 mL/min <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20190731"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="8d3aa56c-8c26-484d-855d-19487c73b32a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                              <paragraph>Co-administration of ibuprofen (800 mg) and famotidine (40 mg) increased ibuprofen C<sub>max</sub> by 15.6% but did not affect its AUC, and increased famotidine AUC and C<sub>max</sub> by 16% and 22%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20190731"/>
                           <component>
                              <section>
                                 <id root="d2bf0ab5-4f1c-4030-86b0-909156872c75"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Aspirin</content>: When NSAIDs were administered with aspirin, the protein binding of NSAIDs were reduced, although the clearance of free NSAID was not altered. The clinical significance of this interaction is not known. See <linkHtml href="#Table3">Table 3</linkHtml> for clinically significant drug interactions of NSAIDs with aspirin <content styleCode="italics">[see <linkHtml href="#S7">Drug Interaction (7)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20190731"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="7bad158b-b52c-47de-b78a-7eb94fc98eb5"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Probenecid, an inhibitor of Organic Aniton Transporter 1 (OAT1) and OAT3</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">In vitro </content>studies indicate that famotidine is a substrate for OAT1 and OAT3.  Following coadministration of probenecid (1500 mg) with a single oral 20 mg dose of famotidine in 8 healthy subjects, the serum AUC<sub>0-10h</sub> of famotidine increased from 424 to 768 ngÃhr/mL and the maximum serum concentration (C<sub>max</sub>) increased from 73 to 113 ng/mL. Renal clearance, urinary excretion rate and amount of famotidine excreted unchanged in urine were decreased. The clinical relevance of this interaction is unknown.</paragraph>
                                 </text>
                                 <effectiveTime value="20190731"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="46a59030-cfc6-4332-a309-64c15ec92d92"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metformin</content>: Famotidine is a selective inhibitor of multidrug and toxin extrusion transporter 1 (MATE-1) but no clinical significant interaction with metformin, a substrate for MATE-1, was observed.</paragraph>
                                 </text>
                                 <effectiveTime value="20190731"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="e787aa7e-a7f1-41ac-9712-be6076ae2369"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20190731"/>
               <component>
                  <section ID="S13.1">
                     <id root="8fa84967-46ab-40ae-9f86-f347d0a13f30"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility</title>
                     <effectiveTime value="20190731"/>
                     <component>
                        <section>
                           <id root="cab8c766-fdb2-46bd-bd3a-339a4bd6757f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Studies to evaluate the potential effects of DUEXIS on carcinogenicity, mutagenicity, or impairment of fertility have not been conducted.</paragraph>
                              <paragraph>In a 106-week study in rats and a 92-week study in mice, famotidine was given at oral doses of up to 2000 mg/kg/day (approximately 122 and 243 times the recommended human dose, respectively, based on body surface area). There was no evidence of carcinogenic potential for famotidine.</paragraph>
                           </text>
                           <effectiveTime value="20190731"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="1900ba0b-ad5f-475b-907b-9d07ef3c8c06"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Famotidine was negative in the microbial mutagen test (Ames test) using <content styleCode="italics">Salmonella typhimurium</content> and <content styleCode="italics">Escherichia coli </content>with or without rat liver enzyme activation at concentrations up to 10,000 Âµg/plate. In <content styleCode="italics">in vivo </content>mouse micronucleus test and a chromosomal aberration test with famotidine, no evidence of a mutagenic effect was observed.</paragraph>
                              <paragraph>In published studies, ibuprofen was not mutagenic in the in vitro bacterial reverse mutation assay (Ames assay). </paragraph>
                           </text>
                           <effectiveTime value="20190731"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="fd9e6fc3-8b85-4a0f-8cdf-5b85be658a95"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>In studies of famotidine in rats at oral doses of up to 2000 mg/kg/day (approximately 243 times the recommended human dose, based on body surface area), fertility and reproductive performance were not affected.</paragraph>
                              <paragraph>In a published study, dietary administration of ibuprofen to male and female rats 8-weeks prior to and during mating at dose levels of 20 mg/kg (0.06-times the MRHD based on body surface area comparison) did not impact male or female fertility or litter size.</paragraph>
                              <paragraph>In other studies, adult mice were administered ibuprofen intraperitoneally at a dose of 5.6 mg/kg/day (0.0085-times the MRHD based on body surface area comparison) for 35 or 60 days in males and 35 days in females. There was no effect on sperm motility or viability in males but decreased ovulation was reported in females.</paragraph>
                           </text>
                           <effectiveTime value="20190731"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="2ee10ed7-f18e-450a-99b2-e17a2cba1f49"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>Two multicenter, double-blind, active-controlled, randomized, 24-week studies of DUEXIS were conducted in patients who were expected to require daily administration of an NSAID for at least the coming 6 months for conditions such as  the following: osteoarthritis, rheumatoid arthritis, chronic low back pain, chronic regional pain syndrome, and chronic soft tissue pain. Patients were assigned randomly, in approximately a 2:1 ratio, to treatment with either DUEXIS or ibuprofen (800 mg) three times a day for 24 consecutive weeks. A total of 1533 patients were enrolled and ranged in age from 39 to 80 years (median age 55 years) with 68% females. Race was distributed as follows: 79% Caucasian, 18% African-American, and 3% Other. Approximately 15% of the patients in Studies 301 and 303 were taking concurrent low-dose aspirin (less than or equal to 325 mg daily), 18% were 65 years of age or older, and 6% had a history of previous upper gastrointestinal ulcer. Although H. pylori status was negative at baseline, H. pylori status was not reassessed during the trials.</paragraph>
                  <paragraph>Studies 301 and 303 compared the incidence of upper gastrointestinal (gastric and/or duodenal) ulcer formation in a total 930 patients taking DUEXIS (ibuprofen and famotidine) and 452 patients taking ibuprofen only, either as a primary or secondary endpoint. In both trials, DUEXIS was associated with a statistically significantly reduction in the risk of developing upper gastrointestinal ulcers compared to taking ibuprofen only during the 6 month study period.	The data are presented below in Tables 4 and 5. Two analyses for each endpoint were conducted. In one analysis patients who terminated early, without an endoscopic evaluation within 14 days of their last dose of study drug, were classified as not having an ulcer. In the second analysis, those patients were classified as having an ulcer. Both analyses exclude patients who terminated study prior to the first scheduled endoscopy at 8 weeks.</paragraph>
                  <table width="75%">
                     <caption>Table 4:  Overall Incidence Rates of Patients Who Developed at Least One Upper Gastrointestinal or Gastric Ulcer - Study 301</caption>
                     <col width="40%" align="left" valign="top"/>
                     <col width="20%" align="center" valign="top"/>
                     <col width="20%" align="center" valign="top"/>
                     <col width="20%" align="center" valign="top"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule"/>
                           <th styleCode="Rrule">DUEXIS<br/>% (n/N)</th>
                           <th styleCode="Rrule">Ibuprofen<br/>% (n/N)</th>
                           <th styleCode="Rrule" valign="middle">
                              <content styleCode="italics">P</content>-value<footnote ID="foot41">Cochran-Mantel-Haenszel test</footnote>
                           </th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Primary endpoint</content>
                           </td>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">Upper gastrointestinal ulcer<footnote ID="foot42">Classifying early terminated patients as NOT having an ulcer</footnote>
                           </td>
                           <td styleCode="Rrule">10.5% (40/380)</td>
                           <td styleCode="Rrule">20.0% (38/190)</td>
                           <td styleCode="Rrule">0.002</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">Upper gastrointestinal ulcer<footnote ID="foot43">Classifying patients who early terminated due to an adverse event, were lost to follow-up, discontinued due to the discretion of the sponsor or the investigator, or did not have an endoscopy performed within 14 days of their last dose of study drug, as having an ulcer</footnote>
                           </td>
                           <td styleCode="Rrule">22.9% (87/380)</td>
                           <td styleCode="Rrule">32.1% (61/190)</td>
                           <td styleCode="Rrule">0.020</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Secondary endpoint</content>
                           </td>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">Â Â Gastric ulcer<footnoteRef IDREF="foot42"/>
                           </td>
                           <td styleCode="Rrule">9.7% (37/380)</td>
                           <td styleCode="Rrule">17.9% (34/190)</td>
                           <td styleCode="Rrule">0.005</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">Â Â Gastric ulcer<footnoteRef IDREF="foot43"/>
                           </td>
                           <td styleCode="Rrule">22.4% (85/380)</td>
                           <td styleCode="Rrule">30.0% (57/190)</td>
                           <td styleCode="Rrule">0.052</td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="75%">
                     <caption>Table 5: Overall Incidence Rate of Patients Who Developed at Least One Gastric or Upper Gastrointestinal Ulcer - Study 303</caption>
                     <col width="40%" align="left" valign="top"/>
                     <col width="20%" align="center" valign="top"/>
                     <col width="20%" align="center" valign="top"/>
                     <col width="20%" align="center" valign="top"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule"/>
                           <th styleCode="Rrule">DUEXIS<br/>% (n/N)</th>
                           <th styleCode="Rrule">Ibuprofen<br/>% (n/N)</th>
                           <th styleCode="Rrule" valign="middle">
                              <content styleCode="italics">P</content>-value<footnote ID="foot51">Cochran-Mantel-Haenszel test</footnote>
                           </th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Primary endpoint</content>
                           </td>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">Â Â Gastric ulcer<footnote ID="foot52">Classifying early terminated patients as NOT having an ulcer</footnote>
                           </td>
                           <td styleCode="Rrule">8.7% (39/447)</td>
                           <td styleCode="Rrule">17.6% (38/216)</td>
                           <td styleCode="Rrule">0.0004</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">Â Â Gastric ulcer<footnote ID="foot53">Classifying patients who early terminated due to an adverse event, were lost to follow-up, discontinued due to the discretion of the sponsor or the investigator, or did not have an endoscopy performed within 14 days of their last dose of study drug, as having an ulcer</footnote>
                           </td>
                           <td styleCode="Rrule">17.4% (78/447)</td>
                           <td styleCode="Rrule">31.0% (67/216)</td>
                           <td styleCode="Rrule">&lt;0.0001</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Secondary endpoint</content>
                           </td>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">Upper gastrointestinal ulcer<footnoteRef IDREF="foot52"/>
                           </td>
                           <td styleCode="Rrule">10.1% (45/447)</td>
                           <td styleCode="Rrule">21.3% (46/216)</td>
                           <td styleCode="Rrule">&lt;0.0001</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">Upper gastrointestinal ulcer<footnoteRef IDREF="foot53"/>
                           </td>
                           <td styleCode="Rrule">18.6% (83/447)</td>
                           <td styleCode="Rrule">34.3% (74/216)</td>
                           <td styleCode="Rrule">&lt;0.0001</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Subgroup analyses of patients who used low-dose aspirin (less than or equal to 325 mg daily), were 65 years and older, or had a prior history of gastrointestinal ulcer are summarized as follows:</paragraph>
                  <paragraph>Of the 1022 patients in clinical studies of DUEXIS, 15% (213 patients) used low-dose aspirin and the results were consistent with the overall findings of the study.  In these clinical studies 16% of patients who used low-dose aspirin who were treated with DUEXIS developed an upper gastrointestinal ulcer compared to 35% of those patients who received only ibuprofen.</paragraph>
                  <paragraph>The clinical trials primarily enrolled patients less than 65 years without a prior history of gastrointestinal ulcer. Of the 1022 patients in clinical studies of DUEXIS, 18% (249 patients) were 65 years of age or older. In these clinical studies, 23% of patients 65 years of age and older who were treated with DUEXIS developed an upper gastrointestinal ulcer compared to 27% of those patients who received only ibuprofen <content styleCode="italics">[see <linkHtml href="#S8.5">Use in Specific Populations (8.5)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>Of the 1022 patients in clinical studies of DUEXIS, 6% had a prior history of gastrointestinal ulcer.  In these clinical studies, 25% of patients with a prior history of gastrointestinal ulcer who were treated with DUEXIS developed an upper gastrointestinal ulcer compared to 24% of those patients who received only ibuprofen.</paragraph>
               </text>
               <effectiveTime value="20190731"/>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="fc580721-5ab7-4a0b-9d96-f2d412a25234"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>DUEXIS (ibuprofen and famotidine) tablets, 800 mg/26.6 mg, are light blue, oval, biconvex, film-coated tablets debossed with "HZT" on one side and supplied as:</paragraph>
                  <table width="50%">
                     <col width="70%" align="left" valign="top"/>
                     <col width="30%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="underline">NDC Number</content>
                           </td>
                           <td>
                              <content styleCode="underline">Size</content>
                           </td>
                        </tr>
                        <tr>
                           <td>75987-010-03</td>
                           <td>Bottle of 90 tablets</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20190731"/>
               <component>
                  <section>
                     <id root="1c06c5fa-aa0d-439b-9adb-2b579bcc10ff"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage</content>
                        </paragraph>
                        <paragraph>Store at 25Â°C (77Â°F); excursions permitted to 15-30Â°C (59-86Â°F). [See USP Controlled Room Temperature]</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="f2cf9479-d85b-4909-a3e4-d48acdd9c9e3"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide).</paragraph>
                  <paragraph>Inform patients, families, or caregivers of the following before initiating therapy with DUEXIS and periodically during the course of ongoing therapy.</paragraph>
               </text>
               <effectiveTime value="20190731"/>
               <component>
                  <section>
                     <id root="90b97391-7409-430e-8ec7-087b19eb8c35"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Cardiovascular Thrombotic Events</content>
                        </paragraph>
                        <paragraph>Advise patients to be alert for the symptoms of cardiovascular thrombotic events, including chest pain, shortness of breath, weakness, or slurring of speech, and to report any of these symptoms to their health care provider immediately <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="d2a2667f-e233-4351-aa0d-7049fae8c4af"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Gastrointestinal Bleeding, Ulceration, and Perforation</content>
                        </paragraph>
                        <paragraph>Advise patients to report symptoms of ulcerations and bleeding, including epigastric pain, dyspepsia, melena, and hematemesis to their health care provider. In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, inform patients of the increased risk for and the signs and symptoms of GI bleeding <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="17f4cc5e-5549-47ed-94a2-ef650378cf41"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hepatotoxicity</content>
                        </paragraph>
                        <paragraph>Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms). If these occur, instruct patients to stop DUEXIS and seek immediate medical therapy <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="327a7a0d-ea9b-4b02-bf84-27fcb2caad13"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Heart Failure and Edema</content>
                        </paragraph>
                        <paragraph>Advise patients to be alert for the symptoms of congestive heart failure including shortness of breath, unexplained weight gain, or edema and to contact their health care provider if such symptoms occur <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="7ad42102-8094-4ab8-80b2-0f758198687a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Anaphylactic Reactions</content>
                        </paragraph>
                        <paragraph>Inform patients of the signs of an anaphylactic reaction (e.g., difficulty breathing, swelling of the face or throat). Instruct patients to seek immediate emergency help if these occur <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="8e00c34c-4b35-4f41-bf3c-b312b3557bbc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Serious Skin Reactions</content>
                        </paragraph>
                        <paragraph>Advise patients to stop DUEXIS immediately if they develop any type of rash and to contact their health care provider as soon as possible <content styleCode="italics">[see <linkHtml href="#S5.11">Warnings and Precautions (5.11)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="8a78d865-bb3e-4abe-b13c-99657d22bacb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Infertility</content>
                        </paragraph>
                        <paragraph>Advise females of reproductive potential who desire pregnancy that NSAIDs, including DUEXIS, may be associated with a reversible delay in ovulation <content styleCode="italics">[see <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="27162da6-4485-49a9-aabf-ecf29b157c99"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Fetal Toxicity</content>
                        </paragraph>
                        <paragraph>Inform pregnant women to avoid use of DUEXIS and other NSAIDs starting at 30 weeks gestation because of the risk of the premature closure of the fetal ductus arteriosus <content styleCode="italics">[see <linkHtml href="#S5.12">Warnings and Precautions (5.12)</linkHtml>
                           </content>, <content styleCode="italics">
                              <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="bf370701-9652-4431-9ac1-c3fc15a254ca"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Avoid Concomitant Use of NSAIDs</content>
                        </paragraph>
                        <paragraph>Inform patients that the concomitant use of DUEXIS with other NSAIDs or salicylates (e.g., diflunisal, salsalate) is not recommended due to the increased risk of gastrointestinal toxicity, and little or no increase in efficacy <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#S5.16">5.16)</linkHtml>, <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.  Alert patients that NSAIDs may be present in the "over the counter" medications for treatment of colds, fever or insomnia.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="d6b51f17-0889-408f-8911-e58c9fa76445"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Use of NSAIDs and Low-Dose Aspirin</content>
                        </paragraph>
                        <paragraph>Inform patients not to use low-dose aspirin concomitantly with DUEXIS until they talk to their health care provider <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="92c633e6-22f9-4cc2-99d7-5100ae8219e4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Nephrotoxicity</content>
                        </paragraph>
                        <paragraph>Patients should be monitored for development of nephrotoxicity (e.g., azotemia, hypertension, and /or proteinuria). If these patients should be instructed to stop therapy and seek immediate medical therapy.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="9009e195-9439-4ddb-952d-0a52eb30bbce"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Creatinine Clearance</content>
                        </paragraph>
                        <paragraph>DUEXIS is not recommended in patients with creatinine clearance &lt;50 mL/min because of seizures, delirium, coma and other CNS effect.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="d586e50b-a296-4ebd-9915-9a7ca94ebd63"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Taking DUEXIS</content>
                        </paragraph>
                        <paragraph>Inform patients that DUEXIS tablets should be swallowed whole, and should not be cut to supply a lower dose. Advise patient not to chew, divide, or crush tablets <content styleCode="italics">[see <linkHtml href="#S2">Dosage and Administration (2)</linkHtml>]</content>.</paragraph>
                        <paragraph>Patients should be instructed that if a dose is missed, it should be taken as soon as possible. However, if the next scheduled dose is due, the patient should not take the missed dose, and should be instructed to take the next dose on time. Patients should be instructed not to take 2 doses at one time to make up for a missed dose.</paragraph>
                     </text>
                     <effectiveTime value="20190731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="2636aef3-0c88-41b2-bd34-0a1f77d9308d"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Distributed by: <br/>Horizon Medicines LLC<br/>Lake Forest, IL 60045</paragraph>
               </text>
               <effectiveTime value="20190731"/>
            </section>
         </component>
         <component>
            <section>
               <id root="2ee4ba04-2d1d-4bd8-92e6-a76534e872a8"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table width="100%">
                     <col width="4%" align="left" valign="top"/>
                     <col width="32%" align="left" valign="top"/>
                     <col width="16%" align="left" valign="top"/>
                     <col width="16%" align="left" valign="top"/>
                     <col width="32%" align="left" valign="top"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule" colspan="5" align="center">Medication Guide<br/>DUEXIS (dew-EX-iss)<br/>(ibuprofen and famotidine)<br/>tablets, for oral use</th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="4">This Medication Guide has been approved by the U.S. Food and Drug Administration.</td>
                           <td align="right" colspan="1">Revised: 07/2019Â Â Â Â </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold" ID="Important">What is the most important information I should know about DUEXIS?<br/>DUEXIS can cause serious side effects including:</content>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Increased risk of a heart attack or stroke that can lead to death</content>. This risk may happen early in treatment and may increase:<list listType="unordered" styleCode="circle">
                                       <item>with increasing doses of medicine containing NSAIDs</item>
                                       <item>with longer use of medicine containing NSAIDs</item>
                                    </list>
                                    <br/>
                                    <content styleCode="bold">Do not take DUEXIS right before or after a heart surgery called a "coronary artery bypass graft (CABG)." Avoid taking DUEXIS after a recent heart attack, unless your healthcare provider tells you to. You may have an increased risk of another heart attack if you take DUEXIS after a recent heart attack.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Increased risk of bleeding, ulcers, and tears (perforation) of the esophagus (tube leading from the mouth to the stomach), stomach and intestines:</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>anytime during use</item>
                              </list>
                           </td>
                           <td colspan="2">
                              <list listType="unordered" styleCode="circle">
                                 <item>without warning symptoms</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="circle">
                                 <item>that may cause death</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Lrule Rrule">
                              <list listType="unordered">
                                 <item>
                                    <caption>Â </caption>
                                    <content styleCode="bold">The risk of getting an ulcer or bleeding increases with:</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>past history of stomach ulcers, or stomach or intestinal bleeding with the use of NSAIDs</item>
                                 <item>taking medicines called "corticosteroids", "anticoagulants", "SSRIs", or "SNRIs"</item>
                                 <item>increasing doses of NSAIDs</item>
                                 <item>longer use of NSAIDs</item>
                              </list>
                           </td>
                           <td/>
                           <td styleCode="Rrule" colspan="2" align="left">
                              <list listType="unordered" styleCode="circle">
                                 <item>smoking </item>
                                 <item>drinking alcohol</item>
                                 <item>older age </item>
                                 <item>poor health</item>
                                 <item>advanced liver disease</item>
                                 <item>bleeding problems</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">You should take DUEXIS exactly as prescribed, at the lowest dose possible and for the shortest time needed. DUEXIS contains a non-steroidal anti-inflammatory drug NSAID (ibuprofen). Do not</content> use DUEXIS with other medicines to lessen pain or fever or with other medicines for colds or sleeping problems without talking to your healthcare provider first, because they may contain an NSAID also.<br/>
                              <content styleCode="bold">DUEXIS may help your acid-related symptoms, but you could still have serious stomach problems.</content> Talk with your healthcare provider.<br/>
                              <content styleCode="bold">DUEXIS contains ibuprofen, an NSAID and famotidine, a histamine H<sub>2</sub>-receptor blocker medicine.</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">What is DUEXIS?</content>
                              <br/>DUEXIS is a prescription medicine used to:<list listType="unordered" styleCode="disc">
                                 <item>relieve the signs and symptoms of rheumatoid arthritis and osteoarthritis.</item>
                                 <item>decrease the risk of developing ulcers of the stomach and upper intestines (upper gastrointestinal ulcers) in people taking ibuprofen for rheumatoid arthritis and osteoarthritis.</item>
                              </list>It is not known if DUEXIS is safe and effective in children. 				</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">Do not take DUEXIS</content>:<br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>if you are allergic to ibuprofen, famotidine, any other histamine H<sub>2</sub>-receptor blocker, or any of the ingredients in DUEXIS. See the end of this Medication Guide for a complete list of ingredients.</item>
                                 <item>if you have had an asthma attack, hives, or other allergic reaction with aspirin or any other NSAIDs.</item>
                                 <item>right before or after heart bypass surgery.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">Before taking DUEXIS, tell your healthcare provider about all of your medical conditions, including if you</content>:<br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>have liver or kidney problems.</item>
                                 <item>have high blood pressure.</item>
                                 <item>have heart problems.</item>
                                 <item>have asthma.</item>
                                 <item>have bleeding problems.</item>
                                 <item>are pregnant or plan to become pregnant. Talk to your healthcare provider if you are considering taking DUEXIS during pregnancy. <content styleCode="bold">You should not take DUEXIS after 29 weeks of pregnancy</content>.</item>
                                 <item>are breastfeeding or plan to breast feed. Ibuprofen and famotidine can pass into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take DUEXIS.</item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements</content>. DUEXIS and some other medicines can interact with each other and cause serious side effects. <content styleCode="bold">Do not start taking any new medicine without talking to your healthcare provider first</content>.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">How should I take DUEXIS?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Take DUEXIS exactly as your healthcare provider tells you to take it.</item>
                                 <item>Your healthcare provider will tell you how many DUEXIS to take and when to take it.</item>
                                 <item>Do not change your dose or stop DUEXIS without first talking to your healthcare provider.</item>
                                 <item>Swallow DUEXIS tablets whole with liquid. Do not split, chew, crush or dissolve the DUEXIS tablet. Tell your healthcare provider if you cannot swallow the tablet whole. You may need a different medicine.</item>
                                 <item>If you forget to take your dose of DUEXIS, take it as soon as you remember. If it is almost time for your next dose, do not take the missed dose. Take the next dose on time. Do not take 2 doses at one time to make up for a missed dose.</item>
                                 <item>You should not take an ibuprofen tablet and famotidine tablet together instead of taking DUEXIS, because they will not work in the same way.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">What are the possible side effects of DUEXIS?<br/>DUEXIS can cause serious side effects, including:<br/>See "<linkHtml href="#Important">What is the most important information I should know about DUEXIS?</linkHtml>
                              </content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" colspan="2">
                              <list listType="unordered" styleCode="disc">
                                 <item>heart attack</item>
                                 <item>stroke</item>
                                 <item>liver problems including liver failure</item>
                                 <item>new or worse high blood pressure</item>
                                 <item>heart failure</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" colspan="3">
                              <list listType="unordered" styleCode="disc">
                                 <item>kidney problems including kidney failure</item>
                                 <item>life-threatening allergic reactions</item>
                                 <item>asthma attacks in people who have asthma</item>
                                 <item>life-threatening skin reactions</item>
                                 <item>low red blood cells (anemia)</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">Other side effects of DUEXIS include</content>: stomach pain, constipation, diarrhea, gas, heartburn, nausea, vomiting, and dizziness.<br/>
                              <content styleCode="bold">Get emergency help right away if you get any of the following symptoms</content>:</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" colspan="2">
                              <list listType="unordered" styleCode="disc">
                                 <item>shortness of breath</item>
                                 <item>chest pain</item>
                                 <item>weakness in one part or side of your body</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" colspan="3">
                              <list listType="unordered" styleCode="disc">
                                 <item>slurred speech</item>
                                 <item>swelling of the face or throat</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">Stop taking DUEXIS and call your healthcare provider right away if you get any of the following symptoms</content>:</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" colspan="2">
                              <list listType="unordered" styleCode="disc">
                                 <item>nausea</item>
                                 <item>more tired or weaker than usual</item>
                                 <item>diarrhea</item>
                                 <item>itching</item>
                                 <item>your skin or eyes look yellow</item>
                                 <item>indigestion or stomach pain</item>
                                 <item>flu-like symptoms</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" colspan="3">
                              <list listType="unordered" styleCode="disc">
                                 <item>vomit blood</item>
                                 <item>there is blood in your bowel movement or it is black and sticky like tar</item>
                                 <item>unusual weight gain</item>
                                 <item>skin rash or blisters with fever</item>
                                 <item>swelling of the arms, legs, hands, and feet</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">If you take too much DUEXIS, call your poison control center at 1-800-222-1222</content>.<br/>These are not all the possible side effects of DUEXIS. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">Other information about NSAIDs</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Aspirin is an NSAID but it does not increase the chance of a heart attack. Aspirin can cause bleeding in the brain, stomach, and intestines. Aspirin can also cause ulcers in the stomach and intestines.</item>
                                 <item>Some NSAIDs are sold in lower doses without a prescription (over-the-counter). Talk to your healthcare provider before using over-the-counter NSAIDs for more than 10 days.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">General information about the safe and effective use of DUEXIS</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use DUEXIS for a condition for which it was not prescribed. Do not give DUEXIS to other people, even if they have the same symptoms that you have. It may harm them.<br/>You can ask your pharmacist or healthcare provider for information about NSAIDs that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">What are the ingredients in DUEXIS?<br/>Active ingredients</content>: ibuprofen and famotidine<br/>
                              <content styleCode="bold">Inactive ingredients</content>: microcrystalline cellulose, anhydrous lactose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, purified water, povidone, titanium dioxide, polyethylene glycol, polysorbate 80, polyvinyl alcohol, hypromellose, talc, FD&amp;C Blue#2/Indigo Carmine Aluminum Lake, and FD&amp;C Blue #1/Brilliant Blue FCF Aluminum Lake.<br/>Distributed by: Horizon Medicines LLC, Lake Forest, IL 60045<br/>For more information, go to www.DUEXIS.com or call 1-866-479-6742.</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20190731"/>
            </section>
         </component>
         <component>
            <section>
               <id root="2a9e9878-c1cc-4307-b91b-1e18b33041d3"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 800 mg/26.6 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>NDC 75987-010-03</paragraph>
                  <paragraph>DUEXIS<sup>Â®</sup>
                     <br/>(ibuprofen and famotidine) Tablets</paragraph>
                  <paragraph>800 mg/26.6 mg<br/>Rx Only</paragraph>
                  <paragraph>90 TABLETS</paragraph>
                  <paragraph>ATTENTION PHARMACIST: Dispense<br/>attached Medication Guide to each patient.</paragraph>
                  <paragraph>HORIZON</paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20190731"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>PRINCIPAL DISPLAY PANEL - 800 mg/26.6 mg Tablet Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="duexis-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>